Navigation Links
ThromboGenics NV - Q3 2009 Business Update
Date:11/4/2009

process development for TB-403 production. ThromboGenics received EUR3 million of the overall EUR5 million success fee.

Corporate Update

ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at the Scrip Awards 2009

    - In September 2009, ThromboGenics was shortlisted for "Biotech
      Company of the Year" and "Licensing Deal of the Year" at the Scrip
      Awards 2009. The Biotech Company of the Year award recognizes the
      progress and achievement a biotech company has made within the last
      twelve months. The Licensing Deal of the Year award acknowledges the
      achievement of a Company in signing a licensing deal that has both
      monetary and strategic benefits to all parties. The awards ceremony
      will take place on November 18, 2009 in London.

    - In October 2009, ThromboGenics announced that it raised
      EUR0.6 million as the result of the exercise of warrants. 90.000 shares
      were created and are now listed on Euronext Brussels. As a result of
      this exercise of warrants, ThromboGenics has 26.417.789 shares
      outstanding.

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB)
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
2. ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
3. ThromboGenics NV Announces Business Update and Half Year Results 2009
4. ThromboGenics NV: Business Update
5. ThromboGenics Announces Business Update and 2008 Full Year Results
6. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
7. ThromboGenics N.V.: Business Update
8. ThromboGenics Announces Half Year Results 2008
9. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
10. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Calif. , June 3, 2015 The ... life of myeloma patients while working toward prevention and ... Annual International Myeloma Working Group (IMWG) Summit June 8-10 ... 100-plus IMWG members will attend the 2015 Summit, which ... the European Hematology Association (EHA).  The focus of the ...
(Date:6/3/2015)... 03, 2015 On April 21, 2015, ... and Communications Committee (11-0) and indicates the legislature's desire to ... energy. , The Committee Chairman supports the bill and would ... by 8,000 GWh and would also like to see any ... , This “Wait List” and timing are extremely important. , ...
(Date:6/3/2015)... CHICAGO , June 3, 2015 /PRNewswire/ ... Company"; LSE: CIR), a specialty biopharmaceutical company focused on ... to the Company,s novel immunotherapy candidates targeting house dust ... the 2015 European Academy of Allergy and Clinical Immunology ... on 6-10 June. Sunday, 7 ...
(Date:6/3/2015)... Innovative biomass supply chain industry leader, ... sponsorship of the first annual Advanced Bioeconomy Feedstocks ... Hotel in New Orleans, June 9-10, the conference brings ... to further the advancements of feedstock by discussing pressing ... logistics, yield improvement and more. , As ...
Breaking Biology Technology:International Myeloma Foundation Brings Together 100 of the World's Top Myeloma Experts June 8-10 in Vienna, Austria for 6th Annual Summit 2International Myeloma Foundation Brings Together 100 of the World's Top Myeloma Experts June 8-10 in Vienna, Austria for 6th Annual Summit 3International Myeloma Foundation Brings Together 100 of the World's Top Myeloma Experts June 8-10 in Vienna, Austria for 6th Annual Summit 4Bmark Energy Announces the Sign-up Deadline for Companies Interested in California’s Direct Access Program is June 12th, 2015 at 5:00pm. 2Circassia to Present at EAACI Annual Meeting, Barcelona, Spain, 6-10 June 2015 2Circassia to Present at EAACI Annual Meeting, Barcelona, Spain, 6-10 June 2015 3Genera to Sponsor Advanced Bioeconomy Feedstocks Conference 2015 2Genera to Sponsor Advanced Bioeconomy Feedstocks Conference 2015 3
... WEST BRIDGEWATER, Mass., Sept. 5 Pressure,BioSciences, Inc. ... has received,approval to CE Mark the Barocycler NEP2320, ... (PCT) instrument. The,Company also announced that it has ... indicating that the Barocycler NEP2320 has been found ...
... CEO of Former Portfolio Company is a Proven Leader ... Genstar Capital, LLC, a middle,market private equity firm that ... healthcare services, industrial technology, business,services and software, today announced ... Advisory Board (SAB). The addition of Mr. Hurt, CEO,of ...
... ,Helps Businesses Find the ... Best ... of,Summit is featured in the September issue of New Jersey Business ... and,Industry Association (NJBIA), the largest state employer organization in,the country. The ...
Cached Biology Technology:Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 2Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 3Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320 4Genstar Names Michael Hurt to Its Strategic Advisory Board 2Boyden's Summit Practice Featured in the September Issue of New Jersey Business Magazine 2
(Date:5/22/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... promotional pricing and making the Wocket generally available for $229 ... Head of Marketing said, "We,ve extended the opportunity to take ... May. To get your wocket at this special price, submit ... on June 1, you,ll receive a unique code that gives ...
(Date:5/20/2015)... 2015 Research ... the addition of the  "5-year Opportunity ... Market"  report to their offering.  ,     ... analyses trends in the iris recognition ... sectors, globally. Despite hardware pricing and ...
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2
... as they are defined in textbooks, are essential ... amounts of energy as they use oxygen. However, ... as Entamoeba histolytica, the causal agent of amoebic ... to support this process. Nevertheless, Entamoeba still contains ...
... student may have figured out why rates of extinction were ... life during one of the greatest ice ages of them ... years ago, late in the Paleozoic Era. , The likely ... this era were singularly equipped to endure severe fluctuations in ...
... new book Hotspots Revisited identifies 34 regions worldwide where ... and amphibians survive within habitat covering just 2.3 percent ... areas of the five largest U.S. states). This habitat ... area equivalent in size to Russia and Australia combined. ...
Cached Biology News:Low level of extinction during ice age linked to adaptability 2Biodiversity hotspots identify conservation priorities 2Biodiversity hotspots identify conservation priorities 3Biodiversity hotspots identify conservation priorities 4Biodiversity hotspots identify conservation priorities 5
Bovine Serum Available Anticoagulants: N-02: Citrate N-04: Heparin (Na) N-06: K2EDTA N-08: Potassium Oxalate N-10: EDTA (Na) N-03: Alsevers N-05: ACD N-07: CPD N-09: K3EDTA N-11:...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
...
Takara's Mutan-Super Express Km Kit is designed to achieve site-directed mutagenesis in just one day. It is based on Oligonucleotide-directed Dual Amber (ODA) method, using the advantages of LA (Long...
Biology Products: